Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | ST6GAL1 | P15907 | 6/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769296 | 1.00 | P2RY2 (0.57) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL20769285 | 0.91 | P2RY2 (0.58) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL4576341 | 0.91 | P2RY2 (0.66) | P2RY2P2RY6P2RY4 | |
| SCHEMBL599382 | 0.90 | P2RY2 (0.57) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL20769283 | 0.90 | P2RY2 (0.57) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL2948365 | 0.90 | P2RY2 (0.57) | P2RY2TSHRGLALMNATHRB | |
| Cytarabine 5'-Phosphate SCHEMBL859799 | 0.89 | P2RY2 (0.68) | P2RY2TSHRGLALMNATHRB | |
| Cytarabine 5'-Phosphate SCHEMBL28286418 | 0.89 | P2RY2 (0.68) | P2RY2TSHRGLALMNATHRB | |
| Cytarabine 5'-Phosphate SCHEMBL859797 | 0.89 | P2RY2 (0.68) | P2RY2TSHRGLALMNATHRB | |
| SCHEMBL25390040 | 0.89 | P2RY2 (0.49) | P2RY2TSHRGLALMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114703184-B | LPA inhibitors and uses thereof | 厦门甘宝利生物医药有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117264948-B | RNAi inhibitor for inhibiting expression of angiotensinogen gene and application thereof | 广州必贝特医药股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117597443-A | RNA inhibitor for inhibiting hepatitis B virus gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2024-02-23 | — | — | CN | claimed |
| WO-2024027809-A1 | RNA INHIBITOR FOR INHIBITING APOC3 GENE EXPRESSION AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2024-02-08 | — | — | WO | claimed |
| CN-117264948-A | RNAi inhibitor for inhibiting expression of angiotensinogen gene and application thereof | 广州必贝特医药股份有限公司 | 2023-12-22 | — | — | CN | claimed |
| CN-115851723-B | RNA inhibitor for inhibiting LPA gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116814621-A | RNA inhibitor for inhibiting APOC3 gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2023-09-29 | — | — | CN | claimed |
| WO-2023169548-A1 | LPA INHIBITOR AND USE THEREOF | 厦门甘宝利生物医药有限公司 | 2023-09-14 | — | — | WO | claimed |
| CN-115851723-A | RNA inhibitor for inhibiting expression of LPA gene and application thereof | 厦门甘宝利生物医药有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-114940991-B | RNA inhibitor for inhibiting hepatitis B virus gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-114703184-A | LPA inhibitor and use thereof | 厦门甘宝利生物医药有限公司 | 2022-07-05 | — | — | CN | claimed |
| CN-114621954-A | RNA inhibitor for inhibiting hepatitis B virus gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-113234725-B | RNA inhibitor for inhibiting PCSK9 gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-113171371-B | RNA inhibitor for inhibiting hepatitis B virus gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2022-01-25 | — | — | CN | claimed |
| CN-113234725-A | RNA inhibitor for inhibiting PCSK9 gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2021-08-10 | — | — | CN | claimed |
| CN-113171371-A | RNA inhibitor for inhibiting hepatitis B virus gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2021-07-27 | — | — | CN | claimed |
| JP-2007501615-A | — | — | 2007-02-01 | — | — | JP | claimed |
| EP-1654362-A2 | 5'-AND 3'-CAPPED APTAMERS AND USES THEREFOR | EYETECH PHARMACEUTICALS, INC. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | (OSI) EYETECH, INC. | 2005-05-05 | — | — | US | claimed |
| WO-2005014814-A2 | 5’-AND 3’-CAPPED APTAMERS AND USES THEREFOR | (OSI) EYETECH, INC. (US) | 2005-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096290-A1 | 5'-and 3'-capped aptamers and uses therefor | FLT4, TEK, FLT1 | P2RY2 1820/4885TSHR 2149/4885GLA 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.